Chuck Schumer’s broken promise on affordable insulin; Intra-Cellular reports positive results in depression study aimed at expanding use of antipsychotic medicine

Taking stock of the drug industry, from the lab to the medicine chest

April 16, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Mariam Zuhaib/AP STAT+ | Chuck Schumer's broken promise on affordable insulin Democrats have achieved only piecemeal progress in making insulin more affordable for millions of people during President Biden's term. By Rachel Cohrs Zhang STAT+ | Intra-Cellular reports positive results in depression study aimed at expanding use of antipsychotic medicine The late-stage clinical trial was aimed at expanding use of the company's antipsychotic medicine Caplyta. By Adam Feuerstein STAT+ | Cerebral to pay $7 million fine and limit health data use for ads under federal order Telehealth company Cerebral will limit the consumer health data it uses for advertising purposes under a new FTC order. By Katie Palmer and Mohana Ravindranath

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser